Viking Therapeutics announced the initiation of the VANQUISH Phase 3 clinical program for its subcutaneous formulation of VK2735 on June 25, 2025. This program represents a significant advancement for the company's dual GLP-1/GIP agonist in the treatment of obesity. The initiation moves VK2735 closer to potential regulatory approval and commercialization.
The VANQUISH program includes two randomized, double-blind, placebo-controlled, multicenter studies. VANQUISH-1 will enroll approximately 4500 adults with obesity, while VANQUISH-2 will target approximately 1100 obese or overweight adults with type 2 diabetes. Both studies will evaluate the efficacy and safety of VK2735 administered once weekly for 78 weeks, with the primary endpoint being the percent change in body weight from baseline.
This comprehensive Phase 3 program underscores Viking's commitment to developing VK2735 as a competitive therapy in the massive obesity market. The company also plans to initiate an additional clinical study later this year to evaluate a monthly maintenance regimen for the subcutaneous formulation, further expanding its strategic approach to weight management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.